logo-loader
viewTransense Technologies

Transense inks deal with Continental

The technology has been adapted to be compatible with Apple’s operating system iOS.

Transense inks deal with Continental
The deal is with ContiTrade, the European arm of Continental

Transense Technologies (LON:TRT) has inked a deal with tyre giant Continental (ETR:CON) to supply it with its latest Translogik tyre inspection probes.

So far, ContiTrade – the European arm of Continental – has ordered 85 kits but Transense expects “significant further orders”, it said without giving financial details.

The technology, used to test tyre pressure in off-road vehicles including combine harvesters, has been adapted to be compatible with Apple’s operating system iOS.

Graham Storey, chief executive of Transense, said: "Having the latest version of the probe used by ContiTrade's large retail network provides Translogik with another significant sales channel.”

The tyre inspection probes, now used in 41 countries, will be used as part of ContiTrade's tyre management system, FleetFox to provide accurate, real-time information on tyre pressure, tread depth and overall tyre condition, including any potential damage.

Bernhard Bamberger, FleetFox development project manager, said: “In terms of tyre data measurement tools, Translogik probes were determined to be the best.”

He added that the firm will begin talks with Transense about a much larger partnership in the future.

Shares in Transense Technologies jumped 9% to 1.25p on Wednesday.

Quick facts: Transense Technologies

Price: 58 GBX

AIM:TRT
Market: AIM
Market Cap: £9.46 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

SkinBioTherapeutics assessing options for a 'rapid trial' of its food supplement

SkinBioTherapeutics PLC (LON:SBTX) CEO Stuart Ashman tells Proactive London's Andrew Scott they're looking at all routes possible to get its psoriasis product into the hands of those that need it as they assesses options for a fast-track human study. It's part of their collaboration with...

1 hour, 23 minutes ago

2 min read